{
  "source": "PA-Med-Nec-Filspari.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2301-3\nProgram Prior Authorization/Medical Necessity\nMedication Filspari™ (sparsentan)\nP&T Approval Date 4/2023, 10/2024, 06/2025, 6/2025\nEffective Date 9/1/2025\n1. Background:\nFilspari (sparsentan) is indicated to slow kidney function decline in adults with primary\nimmunoglobulin A nephropathy (IgAN) who are at risk for disease progression.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Filspari will be approved based on all of the following:\na. Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by renal\nbiopsy\n-AND-\nb. Patient is at risk of disease progression\n-AND-\nc. Used to slow kidney function decline\n-AND-\nd. Used to reduce proteinuria\n-AND-\ne. Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2\n-AND-\nf. Both of the following:\n1) Patient is on a maximized stable dose with one of the following prior to initiating\ntherapy:\na) maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g.,\ncaptopril, enalapril)\n© 2025 UnitedHealthcare Services Inc.\n1\nb) maximally tolerated angiotensin II receptor blocker (ARB) (e.g.,\ncandesartan, valsartan)\n-AND-\n2) Use of renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE\ninhibitors, ARBs), endothelin receptor antagonists [(ERAs) e.g., Letairis,\nOpsumit, Tracleer)], and Tekturna will be discontinued prior to initiating\ntreatment\n-AND-\ng. History of failure, contraindication or intolerance to a 30-day trial of a glucocorticoid\n(e.g., methylprednisolone, prednisone)\n-AND-\nh. Prescribed by or in consultation with a nephrologist\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Filspari will be approved based on the following:\na. Documentation of positive clinical response demonstrated by a reduction in\nproteinuria\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverag",
    "eduction in\nproteinuria\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Filspari [package insert]. San Diego, CA: Traverse Therapeutics, Inc; April 2025.\n2. KDIGO 2021 Glomerular Diseases Guideline. October 2021; 100 (4S).\n© 2025 UnitedHealthcare Services Inc.\n2\nProgram Prior Authorization/Medical Necessity – Filspari\nChange Control\nDate Change\n4/2023 New program\n10/2024 Updated disease progression criteria and criteria that use is to slow\nkidney decline. Updated references.\n6/2025 Updated references.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}